SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues
Launched by THE WELLCOME SANGER INSTITUTE · Feb 11, 2025
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Disease and tissue aging are thought to be influenced by genetic changes, or mutations, acquired throughout life. These mutations provide clues regarding the genetic damage that occurred through the lifetime of the patient, and include mutations caused by environmental factors such as ultraviolet light from sunlight or tobacco smoke affecting the skin or internal tissues, respectively. Other mutations may occur due to errors in copying the genome as cells divide. Once a cell has acquired a mutation, the cell's daughters may inherit it. Eventually clusters of cells carrying the same mutation...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or Female
- • Due to commence systemic treatment for histologically confirmed cancer at a - participating site
- • Age over 18 years
- • Able to give informed consent.
- • Able to give urine, blood and cheek swab samples on two occasions.
- • Likely to complete 3 months of treatment
- Exclusion Criteria:
- • Anyone outside of the inclusion criteria plus individuals who Lack the capacity to provide informed consent and those who do not have a good command of the English language.
- • Any participant who is known to have Hep B, Hep C or HIV
About The Wellcome Sanger Institute
The Wellcome Sanger Institute is a world-renowned genomics research center based in the UK, dedicated to advancing our understanding of human health and disease through cutting-edge genomic science. As a prominent sponsor of clinical trials, the institute leverages its expertise in genetics, bioinformatics, and large-scale data analysis to explore innovative therapeutic approaches and facilitate the translation of research findings into clinical applications. Committed to collaboration and excellence, the Wellcome Sanger Institute plays a pivotal role in the global biomedical research community, driving forward discoveries that have the potential to improve patient outcomes and transform healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, , United Kingdom
Patients applied
Trial Officials
Phil Jones
Principal Investigator
Wellcome Sanger Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported